Prediction of the tissue-specificity of selective estrogen receptor modulators by using a single biochemical method

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 20, 2008, Pages 7171-7176

  Dai, Susie Y ^a   Chalmers, Michael J ^a   Bruning, John ^a   Bramlett, Kelli S ^b,c   Osborne, Harold E ^b   Montrose Rafizadeh, Chahrzad ^b   Barr, Robert J ^b   Wang, Yong ^b   Wang, Minmin ^b   Burris, Thomas P ^b,d   Dodge, Jeffrey A ^b   Griffin, Patrick R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c APPLIED BIOSYSTEMS   (United States)

^d PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Discriminate analysis; Hydrogen deuterium exchange; Mass spectrometry

Indexed keywords

4 HYDROXYTAMOXIFEN; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; BAZEDOXIFENE; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; LASOFOXIFENE; LY 156681; LY 165176; LY 88074; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; CHEMICAL STRUCTURE; CLUSTER ANALYSIS; COMPLEX FORMATION; DEUTERIUM HYDROGEN EXCHANGE; DISCRIMINANT ANALYSIS; DRUG METABOLISM; DRUG TISSUE LEVEL; HUMAN; LIGAND BINDING; MASS SPECTROMETRY; MOLECULAR STABILITY; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; RECEPTOR BINDING; SENSITIVITY ANALYSIS; STRUCTURE ANALYSIS; TISSUE SPECIFICITY;

BIOCHEMISTRY; CELL LINE, TUMOR; CLUSTER ANALYSIS; CRYSTALLOGRAPHY, X-RAY; DATA INTERPRETATION, STATISTICAL; HUMANS; LIGANDS; MASS SPECTROMETRY; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MODELS, STATISTICAL; MOLECULAR CONFORMATION; PROTEIN BINDING; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TISSUE DISTRIBUTION;

EID: 44449102870     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0710802105     Document Type: Article

References (38)

1. McDonnell DP (2006) Mechanism-based discovery as an approach to identify the next generation of estrogen receptor modulators. FASEB J 20:2432-2434.
2. Tamrazi A, Carlson KE, Katzenellenbogen JA (2003) Molecular sensors of estrogen receptor conformations and dynamics. Mol Endocrinol 17:2593-2602.
3. Tamrazi A, Katzenellenbogen JA (2003) Site-specific fluorescent labeling of estrogen receptors and structure-activity relationships of ligands in terms of receptor dimer stability. Methods Enzymol 364:37-53.
4. Tamrazi A, Carlson KE, Rodriguez AL, Katzenellenbogen JA (2005) Coactivator proteins as determinants of estrogen receptor structure and function: Spectroscopic evidence for a novel coactivator-stabilized receptor conformation. Mol Endocrinol 19:1516-1528.
5. Yan X, Broderick D, Leid ME, Schimerlik MI, Deinzer ML (2004) Dynamics and ligand-induced solvent accessibility changes in human retinoid X receptor homodimer determined by hydrogen deuterium exchange and mass spectrometry. Biochemistry 43:909-917.
6. Wales TE, Engen JR (2006) Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev 25:158-170.
7. Quint P, et al. (2006) Structural mobility in human manganese superoxide dismutase. Biochemistry 45:8209-8215.
8. Mandell JG, Falick AM, Komives EA (1998) Identification of protein-protein interfaces by decreased amide proton solvent accessibility. Proc Natl Acad Sci USA 95:14705-14710.
9. Hamuro Y, et al. (2003) Dynamics of cAPK type IIbeta activation revealed by enhanced amide H/2H exchange mass spectrometry (DXMS). J Mol Biol 327:1065-1076.
10. Hamuro Y, et al. (2003) Rapid analysis of protein structure and dynamics by hydrogen/deuterium exchange mass spectrometry. J Biomol Tech 14:171-182.
11. Englander JJ, et al. (2003) Protein structure change studied by hydrogen-deuterium exchange, functional labeling, and mass spectrometry. Proc Natl Acad Sci USA 100:7057-7062.
12. Chalmers MJ, et al. (2006) Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. Anal Chem 78:1005-1014.
13. Bruning JB, et al. (2007) Partial agonists activate PPARg using a helix 12 independent mechanism. Structure (London) 15:1-14.
14. Englander SW (2006) Hydrogen exchange and mass spectrometry: A historical perspective. J Am Soc Mass Spectrom 17:1481-1489.
15. Yan X, et al. (2006) Investigation of ligand interactions with human RXRalpha by hydrogen/deuterium exchange and mass spectrometry. J Am Soc Mass Spectrom 17:1510-1517.
16. Bramlett KS, Burris TP (2003) Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. J Steroid Biochem Mol Biol 86:27-34.
17. Borgna JL, Rochefort H (1980) High-affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite. Mol Cell Endocrinol 20:71-85.
18. Brzozowski AM, et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758.
19. Shiau AK, et al. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937.
20. Chang EC, Frasor J, Komm B, Katzenellenbogen BS (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147:4831-4842.
21. Komm BS, et al. (2005) Bazedoxifene acetate: A selective estrogen receptor modulator with improved selectivity. Endocrinology 146:3999-4008.
22. Ke, HZ, et al. (1998) Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 139:2068-2076.
23. Jordan VC (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 46:883-908.
24. Grese TA, et al. (1997) Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94:14105-14110.
25. Pike AC, et al.(2001) Structural insights into the mode of action of a pure antiestrogen. Structure (London) 9:145-153.
26. Tamrazi A, Carlson KE, Daniels JR, Hurth KM, Katzenellenbogen JA (2002) Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. Mol Endocrinol 16:2706-2719.
27. Blizzard TA, et al. (2004) Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains. Bioorg Med Chem Lett 14:3865-3868.
28. Blizzard, et al. (2004) Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains. Bioorg Med Chem Lett 14:3861-3864.
29. Katzenellenbogen JA, Carlson KE, Katzenellenbogen BS (1985) Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: Limitations to the interpretation of experiments characterizing the activity of individual isomers. J Steroid Biochem 22:589-596.
30. Jordan VC, Collins MM, Rowsby L, Prestwich G (1977) A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75:305-316.
31. Rosati RL, et al. (1998) Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 41:2928-2931.
32. Lindstrom TD, Whitaker NG, Whitaker GW (1984) Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys. Xenobiotica Fate Foreign Compounds Biol Syst 14:841-847.
33. Saeed AI, et al. (2003) TM4: A free, open-source system for microarray data management and analysis. BioTechniques 34:374-378.
34. Morrison, DF (1976) Multivariate Statistical Methods (McGraw-Hill, New York).
35. Mendez MA, Hodar C, Vulpe C, Gonzalez M, Cambiazo V (2002) Discriminant analysis to evaluate clustering of gene expression data. FEBS Lett 522:24-28.
36. Dudoit S, Fridlyand J, Speed TP (2002) Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 97:77-87.
37. Shrake A, Rupley JA (1973) Environment and exposure to solvent of protein atoms. Lysozyme and insulin. J Mol Biol 79:351-371.
38. Geiser AG, et al. (2005) A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation. Endocrinology 146:4524-4535.